



**AUDITORS' REPORT ON HALF YEARLY FINANCIAL RESULTS AND YEAR- TO - DATE RESULTS OF VANTA BIOSCIENCE LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

To

**THE BOARD OF DIRECTORS**  
Vanta Bioscience Ltd  
Umajaya Complex, Rasoolpura,  
Secunderabad.

We have audited the half- yearly standalone financial results of Vanta Bioscience Ltd ('the company') - (Listed on SME Exchange) for the half year ended 31st March, 2018 and the year to date results for the period 01/04/2017 to 31/03/2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified from time to time. These half yearly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, the preparation of which are responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for interim Financial Reporting ( AS 25) prescribed under section 133 of the companies Act, 2013 read with Rule 7 of the Companies ( Accounts) Rules, 2014 and other relevant rules issued there under; or by the Institute of Chartered Accountant of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the Auditing Standards generally accepted in India These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion



E-mail : [mateshca@yahoo.co.in](mailto:mateshca@yahoo.co.in)



**MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us these half- yearly financial results as well as the year-todate results:

1. Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard as modified from time to time
2. Give a true and fair view of the net profit and other financial information for the half year ended 31<sup>st</sup> March 2018 as well as the year to date results for the period from 01.04.2017 to 31.03.2018.

Place: HYDERABAD  
Date: 21/05/2018



For Mathesh & Ramana  
Chartered Accountants

K. Mathesh Reddy  
Partner  
M.No.026285

E-mail : [matheshca@yahoo.co.in](mailto:matheshca@yahoo.co.in)

# 3-6-145, Himayatnagar, Hyderabad - 500 029. Ph: 2322 1822 / 2322 6993 / 2322 2863



# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
Rasoolpura, Secunderabad - 500 003, INDIA.  
Tel : +91 40 6657 5454, 2790 3226  
Fax : +91 40 2790 8708  
Website : www.vantabio.com  
Email : info@vantabio.com  
CIN No. : U74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED  
UMAJAYA COMPLEX, RASOOLPURA, SECUNDERABAD

AUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND YEAR ENDED MARCH 31, 2018

Rs. In Lakh (Except share data)

Sl.No	Particulars	Half Year Ended			Year Ended	
		Six Months Ended	Preceeding six months ended	Corresponding six months ended	Year Ended	Year Ended
		31.03.2018	30.09.2017	31.03.2017	31.03.2018	31.03.2017
		Audited	Unaudited	Audited	Audited	Audited
	<b>Revenue</b>					
1	Revenue from Operations	349.25	49.35	-	398.60	-
2	Other Income	5.28	-	-	5.28	-
3	<b>Total Revenue(1+2)</b>	<b>354.53</b>	<b>49.35</b>	-	<b>403.88</b>	-
	<b>Expenses</b>					
a)	Cost of material Consumed	27.64	4.62	-	32.26	-
b)	Purchase of Stock In Trade	-	-	-	-	-
c)	Changes in Inventories of Finished Goods, Work In progress and stock in Trade	-	-	-	-	-
d)	Employee Benefit Expenses	149.31	11.80	-	161.11	-
e)	Finance Cost	15.80	3.84	-	19.64	-
f)	Depreciation and Amortization Exp	40.84	16.38	-	57.22	-
g)	other Expenses	95.73	6.42	-	102.15	-
		<b>329.32</b>	<b>43.06</b>	-	<b>372.38</b>	-
5	<b>Profit Before Exceptional and Extraordinary Items (3-4)</b>	<b>25.21</b>	<b>6.29</b>	-	<b>31.50</b>	-
6	Exceptional Items	-	-	-	-	-
7	<b>Profit Before Extraordinary Items (5-6)</b>	<b>25.21</b>	<b>6.29</b>	-	<b>31.50</b>	-
8	Extraordinary Items	-	-	-	-	-
9	<b>Profit Before Tax(7+8)</b>	<b>25.21</b>	<b>6.29</b>	-	<b>31.50</b>	-
10	<b>Tax Expenses</b>					
a)	Current Tax	4.80	1.20	-	6.00	-
b)	Deffered Tax	15.32	7.45	-	22.77	-
11	<b>Profit/(loss) for the period from continuing Operations (9-10)</b>	<b>5.09</b>	<b>-2.36</b>	-	<b>2.73</b>	-
12	Profit/(loss) Discontinuing Operations	-	-	-	-	-
13	Tax Expenses of Discontinuing Operations	-	-	-	-	-
14	<b>Profit/(loss) from Discontinuing Operations (12+13)</b>	<b>-</b>	<b>-</b>	-	<b>-</b>	-
15	<b>Profit &amp; loss for the Period (11+14)</b>	<b>5.09</b>	<b>-2.36</b>	-	<b>2.73</b>	-
16	<b>Earning Per Share of Rs. 10 Each (Not Annualised)</b>					
a)	Basic(Rs.)	0.09	-	-	0.05	-
b)	Diluted (Rs.)	0.09	-	-	0.05	-

For VANTA BIOSCIENCE LIMITED

*D. D. Raju*

DOPESH RAJA MULAKALA  
MANAGING DIRECTOR  
DIN: 01176660  
Secunderabad  
21st May 2018



For VANTA BIOSCIENCE LIMITED

*S. Venkatesh Rao*

VENKATA RAO SADHANALA  
CEO & WHOLE TIME DIRECTOR  
DIN: 02906370  
Secunderabad  
21st May 2018



The Right Dose of  
Intelligent Toxicology

Research Center :  
K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex,  
Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.  
Tel : 044 6790 1600



# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
 Rasoolpura, Secunderabad - 500 003, INDIA.  
 Tel : +91 40 6657 5454, 2790 3226  
 Fax : +91 40 2790 8708  
 Website : www.vantabio.com  
 Email : info@vantabio.com  
 CIN No. : U74999TG2016PLC109280

VANTA BIOSCIENCE LIMITED  
 NO.02/G/308/G NO.3/FF/SF/1-20-248,UMAJAY COMPLEX, RASOOLPURA, SECUNDERABAD -500003,  
 TELANGANA

STATEMENT OF ASSETS AND LIABILITIES AS ON 31.03.2018		
Particulars	As at 31.03.2018	As at 31.03.2017
<b>1. Equity and Liabilities</b>		
<b>I. Share holder's Funds</b>		
a)Share capital	572.80	364.60
b)Reserves & Surplus	1,085.93	250.40
	<b>1,658.73</b>	<b>615.00</b>
<b>II. Non Current Liabilities</b>		
a)Deferred Tax liabilities (Net)	22.76	-
b)Long term Borrowings	998.01	750.00
c) Long term provisions	-	-
	<b>1,020.77</b>	<b>750.00</b>
<b>III. Current Liabilities</b>		
a) Short Term Borrowings	119.85	-
b) Trade payables	19.43	-
c) other Current Liabilities	94.34	9.59
d) Short Term Provisions	6.00	-
	<b>239.62</b>	<b>9.59</b>
<b>Total</b>	<b>2,919.12</b>	<b>1,374.59</b>
<b>2. Assets</b>		
<b>I. Non Current Assets</b>		
a) Fixed Assets		
Tangible Assets	1,497.10	1,294.61
Research & Development	486.23	-
	-	-
b)Other Non current Assets	35.04	27.48
	<b>2,018.37</b>	<b>1,322.09</b>
<b>II. Current Assets</b>		
a) Current Investments	450.00	-
b)Inventories	302.44	-
c)Trade Receivable	33.02	-
d)Cash & Bank Bal	8.73	44.45
e)Short Term Loans & Advances	54.75	-
f)Other Current Assets	51.80	8.05
	<b>900.75</b>	<b>52.50</b>
<b>Total</b>	<b>2,919.12</b>	<b>1,374.59</b>

For VANTA BIOSCIENCE LIMITED

*M. Dopesha Raja*  
**DOPESH RAJA MULAKALA**  
 MANAGING DIRECTOR  
 DIN: 01176660  
 Secunderabad  
 21st May 2018



For VANTA BIOSCIENCE LIMITED

*S. Venkatesh Rao*  
**VENKATA RAO SADHANALA**  
 CEO & WHOLE TIME DIRECTOR  
 DIN: 02906370  
 Secunderabad  
 21st May 2018





# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
 Rasoolpura, Secunderabad - 500 003, INDIA.  
 Tel : +91 40 6657 5454, 2790 3226  
 Fax : +91 40 2790 8708  
 Website : www.vantabio.com  
 Email : info@vantabio.com  
 CIN No. : U74999TG2016PLC109280

### Notes:

1. The above said financial results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 21st May 2018.
2. The above operations reflect only 15% of total capacity of the Unit, this being the 1st year of the commercial Operations
3. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of capital and Disclosure requirements) regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under exempted from the compulsory requirement of adoption of IND AS, As the company is covered under the exempted category, it has not adopted IND AS for preparation of Financial Statements.
3. Statement of Assets and Liabilities as on 31st March 2018 is enclosed herewith
4. The statutory auditors have given an unmodified opinion in their report for the financials for the period ended 31st March 2018. These financials of the Company will also be available on the Company's website www.vantabio.com
5. There were no investor complaints received/pending as at 31st March 2018
6. The financial figures for the previous half year/year have been regrouped/reclassified, wherever necessary to confirm to current period
7. We hereby inform that there was no deviation in the utilization of Public issue proceeds from the objects as stated in the prospectus of the issue, as required under regulation 32(1) (a) of the SEBI (Listing Obligations and disclosure Requirement) Regulation 2015

Amount in Lacs

Category	Projected Utilization of Funds (As per offer Document)	Actual utilization of Funds
Augumenting Additional Working Capital Requirement	679.40	229.40
General Corporate Purpose	26.60	26.60
Public Issue Expenses	50.00	50.00
<b>Total</b>	<b>756.00</b>	<b>306.00</b>

8. The statement includes the results of half year ended March 31, 2018, being the balancing figure between the audited figures in respect of the full financial year and the unaudited figures of the previous half year
9. The Company presently engaged in the business of preclinical Activities, Hence there is no separate segment reporting required

For VANTA BIOSCIENCE LIMITED

*M. Dopesha Raja*

**DOPESH RAJA MULAKALA**  
 MANAGING DIRECTOR  
 DIN: 01176660  
 Secunderabad  
 21st May 2018



For VANTA BIOSCIENCE LIMITED

*S. Venkatarao*

**VENKATA RAO SADHANALA**  
 CEO & WHOLE TIME DIRECTOR  
 DIN: 02906370  
 Secunderabad  
 21st May 2018



Research Center :

K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex,  
 Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201,  
 Tel : 044 6790 1600